




The relative strengths and weaknesses of Regulus Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Regulus Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 350%, being 87% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	134,258
Cost of Goods Sold	0
Intangible Assets	1,081
Liabilities, Current	12,632
Liabilities, Non-Current	2,308
Other Assets	344
Other Compr. Net Income	64
Other Expenses	34
Other Liabilities	2,065
Other Net Income	-1,800
Other Revenues	21,614
Property and Equipment	5,400
Research and Development	56,387
Selling, General and Administrative Expense	19,130

Output Variable	Value in 1000 USD
Assets	141,083
Liabilities	17,005
Expenses	75,551
Revenues	21,614
Stockholders Equity	124,078
Net Income	-55,737
Comprehensive Net Income	-55,705
BaseVar	128,558
ECR before LimitedLiability	272%
Economic Capital Ratio	350%